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New Class of Radially Adjustable Stentrievers for
Acute Ischemic Stroke
Primary Results of the Multicenter TIGER Trial
Rishi Gupta , MD, MBA*; Jeffrey L. Saver, MD*; Elad Levy, MD; Osama O. Zaidat, MD, MS; Dileep Yavagal , MD;
David S. Liebeskind, MD; Ahmad Khaldi, MD, MS; Bradley Gross, MD; Michael Lang, MD; Sandra Narayanan, MD;
Brian Jankowitz, MD; Kenneth Snyder, MD; Adnan Siddiqui, MD; Jason Davies, MD; Eugene Lin , MD; Ameer Hassan, MD;
Ricardo Hanel, MD; Amin Aghaebrahim, MD; Ritesh Kaushal, MD; Ali Malek , MD; Nils Mueller-Kronast, MD; Robert Starke, MD;
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Ronald F. Budzik, MD; Peter Pema, MD; Nirav Vora, MD; M. Asif Taqi, MD; Edgar Samaniego, MD; Qingliang Tony Wang, MD, PhD;
Erez Nossek, MD; Guilherme Dabus , MD; Italo Linfante, MD; Ajit Puri, MD; Eitan Abergel, MD; Sidney Starkman, MD;
Satoshi Tateshima, MD; Ashutosh P. Jadhav, MD, PhD, for the TIGER Trial Investigators
BACKGROUND AND PURPOSE: The Tigertriever is a novel, radially adjustable, fully visible, stentriever that permits the operator to
align radial expansion with target vessel diameters. This multicenter trial compared the Tigertriever’s effectiveness and safety
compared with established stent retrievers.
METHODS: Single arm, prospective, multicenter trial comparing the Tigertriever to efficacy and safety performance goals derived
from outcomes in 6 recent pivotal studies evaluating the Solitaire and Trevo stent-retriever devices with a lead-in and a mainstudy phase. Patients were enrolled if they had acute ischemic stroke with National Institutes of Health Stroke Scale score ≥8
due to large vessel occlusion within 8 hours of onset. The primary efficacy end point was successful reperfusion, defined as core
laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia score 2b-3 within 3 passes of the Tigertriever. The primary
safety end point was a composite of 90-day all-cause mortality and symptomatic intracranial hemorrhage. Secondary efficacy
end points included 3-month good clinical outcome (modified Rankin Scale score 0–2) and first-pass successful reperfusion.
RESULTS: Between May 2018 and March 2020, 160 patients (43 lead-in, 117 main phase) at 17 centers were enrolled and treated
with the Tigertriever. The primary efficacy end point was achieved in 84.6% in the main-study phase group compared with the 63.4%
performance goal and the 73.4% historical rate (noninferiority P<0.0001; superiority P<0.01). The first pass successful reperfusion
rate was 57.8%. After all interventions, successful reperfusion (modified Thrombolysis in Cerebral Ischemia score ≥2b) was achieved
in 95.7% and excellent reperfusion (modified Thrombolysis in Cerebral Ischemia score 2c-3) in 71.8%. The primary safety composite
end point rate of mortality and symptomatic intracranial hemorrhage was 18.1% compared with the 30.4% performance goal and
the 20.4% historical rate (noninferiority P=0.004; superiority P=0.57). Good clinical outcome was achieved in 58% at 90 days.
CONCLUSIONS: The Tigertriever device was shown to be highly effective and safe compared with Trevo and Solitaire devices to
remove thrombus in patients with large-vessel occlusive stroke eligible for mechanical thrombectomy.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03474549.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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BGC
balloon guide catheter
CT
computed tomography
DSMB
data and safety monitoring board
IQR
interquartile range
IV tPA	intravenous tissue-type plasminogen
activator
mRS
modified Rankin Scale
mTICI	modified Thrombolysis in Cerebral
Ischemia
NIHSS	National Institutes of Health Stroke
Scale
PG
performance goal
sICH
symptomatic intracranial hemorrhage
TIGER	Treatment With Intent to Generate Endovascular Reperfusion

B

ased on convergent evidence from major clinical
trials of reperfusion efficacy and improved clinical
outcomes, endovascular thrombectomy with stent
retrievers has become the standard of care for patients
with large vessel occlusion ischemic strokes.1–8 A metaanalysis of 5 randomized trials demonstrated the number
needed to treat with thrombectomy is 1 in 2.6 to improve
3-month global disability outcome by 1 or more levels on
the modified Rankin Scale (mRS).9 However, while quite
substantial, the benefits conveyed by first-generation
stent retrievers are constrained by less than maximal
reperfusion rates achieved with these devices. In pooled,
individual participant data meta-analyses of the pivotal
trials, failure to achieve successful reperfusion (modified Thrombolysis in Cerebral Ischemia [mTICI] 2b-3)
occurred in 29% of patients and failure to achieve complete reperfusion (mTICI 3) in 67%.9 Accordingly, developing additional endovascular thrombectomy devices
with performance characteristics comparable or better
than established stent retrievers is desirable.
The Tigertriever (Rapid Medical) is a novel operatoradjustable stent retriever that affords the interventionalist incremental control over the radial diameter and radial
force of the thrombectomy basket. The design is intended
to facilitate alignment of the mesh with the anatomy of
the occluded vessel and to increase internalization of the
thrombus within the device, thereby facilitating retrieval
and reducing downstream embolization (Figure 1A; Figure
I in the Data Supplement). The device has had CE mark,
the European Union certification indicating conformity with
health, safety, and environmental protection, since 2016
and has shown promising signals of efficacy and safety in
preliminary case series reported by European centers.10–12
The TIGER trial (Treatment With Intent to Generate Endovascular Reperfusion) was a single-arm, multicenter, prospective study assessing the efficacy and
Stroke. 2021;52:1534–1544. DOI: 10.1161/STROKEAHA.121.034436

safety of the Tiger-21 and Tiger-17 retrievers. The study
employed an objective performance criterion, noninferiority design, comparing efficacy and safety of the Tigertriever with performance goals derived from adjudicated
outcomes in 6 completed prospective trials of 2 FDAapproved predicate stent retrievers, Solitaire (Medtronic)
and Trevo (Stryker).1–4,13,14

METHODS
Study Design
The data that support the findings of this study are available from
the corresponding author on reasonable request and with approval
from the TIGER investigators. The primary TIGER Study hypothesis was that the Tigertriever device would achieve successful
reperfusion performance within 3 attempts would be superior
to the performance goal established using Bayesian meta-analysis of 6 recent pivotal trials of the Solitaire and Trevo stentretriever devices—TREVO 2 (Thrombectomy Revascularization
of Large Vessel Occlusions in Acute Ischemic Stroke),13 SWIFT
(SOLITAIRE FR With the Intention for Thrombectomy),14 MR
CLEAN (Multicenter Randomized Clinical Trial of Endovascular
Treatment for Acute Ischemic Stroke in the Netherlands),1
ESCAPE (Endovascular Treatment for Small Core and Anterior
Circulation Proximal Occlusion With Emphasis on Minimizing
CT to Recanalization Times),4 REVASCAT (Randomized Trial of
Revascularization With Solitaire FR Device Versus Best Medical
Therapy in the Treatment of Acute Stroke due to Anterior
Circulation Large Vessel Occlusion Presenting Within Eight
Hours of Symptom Onset),3 and SWIFT PRIME (Solitaire With the
Intention for Thrombectomy as Primary Endovascular Treatment).2
The study was overseen by an executive committee, composed of academic investigators, and an independent data
and safety monitoring board (DSMB) (Table I in the Data
Supplement). The DSMB consisted of an independent stroke
neurologist and 2 independent neurointerventionalists, who did
not enroll patients, and a biostatistician. At the level of individual
events, the DSMB adjudicated all safety end points, including hemorrhages and serious adverse events. At the level of
aggregate study data, the DSMB acted in an expert supervisory
capacity and monitored subject safety and the conduct of the
study. Central readers at a core imaging laboratory assessed
qualifying diagnostic catheter angiography to determine location of the target occlusion, and rated reperfusion grades on
angiograms obtained after every pass of the Tigertriever device,
every pass of rescue therapy, and end of the procedure. The core
laboratory imaging readers also assessed baseline and 24-hour
post-procedure computed tomography (CT) or magnetic resonance imaging scans to verify study entry criteria and determine
the presence and type of any postprocedure intracranial hemorrhage. The sponsor, Rapid Medical, and its contracted Contract
Research Organization (Genae Americas) were responsible for
logistical operations, data management, and monitoring of the
trial. The study protocol was approved by the institutional review
board or ethics committee at each participating site.

Population and Participating Centers
All patients or their legally authorized representative provided
written informed consent before enrollment. Patients aged 18
May 2021   1535
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Alberta Stroke Program Early CT Score 6–10 for CT-qualifying
or diffusion restriction volume ≤50 mL for magnetic resonance
imaging-qualifying anterior circulation cases; patient being
either (1) eligible for, and received, IV tPA (intravenous tissuetype plasminogen activator) within 3 hours of symptom onset
or (2) ineligible for IV tPA treatment; and anticipated device
deployment within 8 hours of last known well. Key exclusion
criteria included stenosis or occlusion in the deployment site
or in a proximal vessel that would prevent device access to the
thrombus or require angioplasty or stenting to enable device
access to the thrombus. The treatment start inclusion criterion
of within 8 hours, rather than also 8 to 24 hours with advanced
imaging selection, was selected as initial trial design discussions
and review with the Food and Drug Administration occurred
before the reporting of results of late window trials. Physicians
were trained in the use of the device on a bench vascular model
before any procedures were done. In addition, participating
sites that had no experience with the Tigertriever device were
required to first participate in a lead-in phase before participating in the main-study phase for primary end point analysis.
During the lead-in phase, up to 4 patients per clinical site were
enrolled. The lead-in phase was completed by the site either (1)
achieving 2 successive successful reperfusions (mTICI 2b or
higher) or (2) performing 4 cases. Patients enrolled in the leadin phase were consented, treated, and followed according to the
clinical protocol, in the same manner as the main-study patients.

Procedure

Figure 1. Tigertriever device and chart of patient flow through
study.
A, Tigertriever device including external handle for the operator to control
the degree of expansion of the stent retriever. Fine wire mesh mounted
on a flexible shaft. The design of the wire mesh (magnified view) is
optimized to penetrate the clot and encapsulate it during retrieval. B,
Patient screening, enrollment, treatment, and follow-up. ICH indicates
intracranial hemorrhage; LVO, large vessel occlusion; mRS, modified
Rankin Scale; and NIHSS, National Institutes of Health Stroke Scale.

to 85 years were eligible for the study if they had acute ischemic stroke with new moderate-to-severe neurological deficits,
angiographically confirmed occlusion in the intracranial internal
carotid, middle cerebral (M1 or M2 segment), basilar, or vertebral artery, and could undergo endovascular therapy (at least 1
Tigertriever deployment in the target artery) within 8 hours of
last known well. Full study entry criteria are shown in the Data
Supplement (Table II in the Data Supplement). Key inclusion criteria included the following: prestroke mRS score ≤1; baseline
National Institutes of Health Stroke Scale (NIHSS) score 8–29;
1536   May 2021

Site of arterial access and anesthesia mode were based on
operator preference at the enrolling center. The selection of
guide catheter type (balloon guide catheter (BGC) versus nonBGC) and use of an intermediate catheter was also at the discretion of the operator. After placement of the guide catheter
in the target vessel, a roadmap was constructed and the microcatheter was navigated across the clot. The Tigertriever was
deployed and the amount of expansion of the device was based
on vessel diameter and clot length.
Two versions of the Tigertriever device were available: The
standard version (Tigertriever) has a net length of 32 mm (unexpanded form) and can expand up to 6 mm diameter, can be delivered through a microcatheter with an internal diameter of 0.021
inches. And a smaller version (Tigertriever 17) has a net length
of 23 mm (unexpanded form) and can be delivered through a
microcatheter with an internal diameter of 0.017 inches. It can
expand up to 3 mm diameter. The device deployment, dwell
time, and number of expansions/deflations were based on
the instructions for use. The first pass was required to be with
the Tigertriever for inclusion in the trial. Up to 3 passes of the
Tigertriever were permitted to achieve successful reperfusion
(mTICI, 2b-3). For each pass, a new Tigertriever device was used
and the total number of passes and devices used were recorded.
After 3 attempts, rescue therapy could be used by the operator. Rescue therapy could consist of use of another mechanical
thrombectomy device, angioplasty, intraarterial tPA, or intracranial stenting at the discretion of the treating physician. The
Tigertriever could not be used after a rescue attempt and for primary efficacy analysis when revascularization was unsuccessful
after Tigertriever attempts it was considered a failure to achieve
the end point. Imaging with CT or magnetic resonance imaging
was obtained at 24 hours to assess for intracranial hemorrhage.

Stroke. 2021;52:1534–1544. DOI: 10.1161/STROKEAHA.121.034436
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Outcomes
Primary Efficacy End Point
The primary efficacy end point was successful reperfusion,
defined as achieving mTICI 2b-3 within 3 passes with the
Tigertriever without use of rescue therapy. All angiograms
were interpreted by an experienced neurointerventionalist readers at the independent core imaging laboratory, who
assigned scores using the mTICI scale.15 The core imaging
laboratory mTICI ratings were used for assessment of the primary efficacy end point.

The PG for safety primary end point was defined as the
incidence in the 6 trials cited above, plus a statistical margin
of 10%. Thus, the PG was 30.4% (18.2% mortality+2.2%
sICH+10% noninferiority statistical margin). For primary safety,
the hypothesis test was performed at an overall 2-sided alpha
level of 0.05 using exact binomial methods, in which the upper
confidence bound on the observed incidence of revascularization is compared with the PG.
The primary study population was the main-study phase
group. Sensitivity analysis was performed at regulatory request
on the combined lead-in/main-study phase population). To
evaluate Tigertriever device performance in vessels with of
varied size, the study population was divided into 2 vessel
diameter categories, ≥2 and <2 mm, and performance compared across the groups.

Primary Safety End Point
The primary safety end point was defined as the composite of
all-cause mortality at 90±14 days and symptomatic intracranial
hemorrhage (sICH) within 24 (18–36) hours from the study procedure. sICH was defined as any parenchymal hematoma type 2,
remote intracerebral hemorrhage, subarachnoid hemorrhage, or
intraventricular hemorrhage that is the predominant cause of an
NIHSS deterioration of 4 or more points at 24 hours, as adjudicated by the DSMB (modified Heidelberg Bleeding Classification
criteria).16 The independent core imaging laboratory assessed
all 24-hour CT/MR images and radiologically classified hemorrhages as hemorrhagic infarction types 1 or 2, parenchymal
hematoma types 1 or 2, remote intracerebral hemorrhage, subarachnoid hemorrhage, and intraventricular hemorrhage.

Secondary End Points
Prespecified secondary efficacy end points for the study were (1)
good clinical outcome (mRS score 0–2 at 90 days; (2) first pass
successful reperfusion (mTICI 2b-3); (3) health-related quality
of life at 90 days, assessed with the EQ-5D2,17; and (4) granular
level of disability at 90 days, assessed with the Academic Medical
Center Linear Disability Score.18,19 Prespecified secondary safety
end points were (1) asymptomatic intracranial hemorrhage within
24 hours (18–36 hours) of procedure; (2) neurological deterioration within 24 hours after procedure, defined as a NIHSS
increase of 4 points or more; and (3) embolization to previously
uninvolved vascular territories.

Statistical Analysis
The performance goal for the efficacy primary end point was
defined as the incidence in the 6 trials cited below, minus
a noninferiority statistical margin of 10%, the same clinically relevant threshold employed in the registration trials of
stent-retrievers, SWIFT and TREVO 2,9,13 therefore, giving a
performance goal (PG) of 73.4%−10%=63.4%. The pooled
incidence was derived from the following 6 studies: TREVO
2, SWIFT,1 MR CLEAN, ESCAPE, REVASCAT, and SWIFT
PRIME.1–4,9,13 For this efficacy end point, the primary noninferiority hypothesis test was performed at an overall 2-sided
alpha level of 0.05 using exact binomial methods, in which the
lower confidence bound on the observed incidence of reperfusion is compared with the PG. If noninferiority was demonstrated, superiority was then tested in a post hoc hierarchical
manner. The study statistical design is shown graphically in
Figure IIA in the Data Supplement.
Stroke. 2021;52:1534–1544. DOI: 10.1161/STROKEAHA.121.034436

RESULTS
Between May 2018 and March 2020, 1712 patients
were preliminarily screened, 183 consented before angiography, and 160 met angiographic and device access
criteria for full study enrollment. Patients were enrolled at
17 study centers (16 US centers—159 patients, 1 Israeli
center—1 patient; Table I in the Data Supplement) and
included 43 lead-in phase and 117 main-study phase
patients. Figure 1B shows the screening, enrollment,
treatment, and follow-up flow of the study population.
Patient baseline characteristics are shown for the mainstudy phase and combined lead-in/main-study phase
cohorts in Table 1 (Table III in the Data Supplement shows
patient characteristics for the lead-in phase patients alone;
Tables IV and V in the Data Supplement compare patient
characteristics and outcomes in the current trial with those
of the 6 trials contributing to the performance goal and
the more recent ARISE II trial [Analysis of Revascularization in Ischemic Stroke With EmboTrap]). In the main-study
phase cohort, patient age was mean 65±15 years, 61.5%
were men, and median baseline NIHSS 17 (interquartile
range [IQR], 12–21). The median Alberta Stroke Program
Early CT score was 9 (IQR, 8–10). Target occlusion location was in the anterior circulation in 97.4% of patients,
with the most common sites the M1 middle cerebral artery
(57.3%) and intracranial internal carotid artery (20.5%).
Time from last known normal to puncture was 172 minutes (IQR, 128–273), and a majority (65.8%) of patients
received intravenous t-PA before thrombectomy. A BGC
was used in 29.9% of the procedures (21.4% BGC alone
and 8.5% BGC+regional aspiration).

Primary Efficacy End Point and Reperfusion
Results
In the primary analysis main-study phase population,
the Tigertriever achieved the primary end point of successful reperfusion (mTICI 2b-3) within 3 passes and
without rescue therapy in 99 of 117 patients, 84.6%
(95% CI, 78.1%–91.2%), compared with the 63.4%
May 2021   1537
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4 days (or discharge if sooner), 30 days, and 90 days.
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Table 1. Patient and Procedure Characteristics for MainStudy and Combined Lead-In/Main-Study Patients
TIGER
Main-study
(n=117)

All (n=160)

Age, y; mean (SD)

65 (15)

66 (15)

Male sex, n (%)

72 (61.5%)

92 (58%)

Race, n (%)
White

99 (84.6%)

134 (83.7%)

Black

17 (14.5%)

24 (15%)

Asian

1 (0.85%)

2 (1.25%)

16 (13.7%)

24 (15%)

Hispanic ethnicity, n (%)
NIHSS score
Mean (SD)

17.4 (5.6)

17.6 (5.6)

Median (IQR)

17 (12–21)

18 (13–22)

Baseline CT ASPECTS
Mean (SD)

8.9 (1.1)

8.8 (1.2)

Median (IQR)

9 (8–10)

9 (8–10)

Prestroke mRS, n (%)

(n=117)

(n=156)

0–1

116 (99.2%)

155 (99.4%)

0

93 (79.5%)

127 (81.4%)

1

23 (19.7)

28 (17.8%)

Body mass index, median (IQR)

29.5 (25–35)

30.4 (25.7–36.2)

Medical history, n (%)
Hypertension

89 (76%)

126 (78.8%)

Diabetes

36 (30.8%)

52 (32.5%)

Atrial fibrillation

47 (40.2)

60 (37.5%)

Dyslipidemia

57 (48.7%)

81 (50.6%)

Previous MI/CAD

23 (19.7%)

34 (21.3%)

16 (13.7%)

20 (12.5%)

77 (65.8%)

111 (69.4%)

67 (57.3%)

87 (54.4%)

 Previous ischemic stroke/transient
ischemic attack
Intravenous tPA failure
Proximal occlusion location, n (%)
M1 middle cerebral artery
M2 middle cerebral artery

23 (19.7%)

37 (23.2%)

Internal carotid artery

24 (20.5%)

31 (19.4%)

Basilar

3 (2.6%)

5 (3.2%)

Occlusion side (left)
 Last known well to arterial puncture, min; median (IQR)

48 (41%)

80 (50%)

172
(128.3–273)

179
(127.5–293)

Procedure aspects

The full distribution of reperfusion outcomes is shown
in Figure 2A. The rate of excellent reperfusion (mTICI
2c-3) within 3 passes of the Tigertriever was 63.2%
and 71.8% after all interventions. The frequency of first
pass excellent reperfusion (mTICI 2c-3) was 41.4%
and of first pass substantial reperfusion (mTICI 2b-3)
57.8%. The mean number of passes with the Tigertriever was 1.8±0.9. The rates of reperfusion achieved
with each device size (Tigertriever and Tigertriever 17)
and in each target artery are reported in Text I in the in
the Data Supplement.
Rescue therapy was employed in 33 of 117 (28.2%)
main-study phase patients (frequency of other mechanical thrombectomy devices, angioplasty, intraarterial
thrombolysis, and intracranial stenting shown in Table VI
in the Data Supplement). In 5, at the interventionalist’s
discretion, a different device was used before reaching 3
passes with Tigertriever. Per protocol, these were counted
as failures despite not having not made 3 attempts with
Tigertriever. In 13, the additional devices were used at
interventionalist discretion to further improve reperfusion
despite mTICI ≥2b having been attained within 3 passes
of the Tigertriever. Per protocol, these were counted
as Tigertriever successes in achieving mTICI≥2b Final
reperfusion rates after all interventions were 95.7%
mTICI 2b-3; 71.8% mTICI 2c-3; and 41.9% mTICI 3.
Median time from arterial puncture to successful reperfusion (mTICI 2b-3) was 24 minutes (IQR, 16–38).
Primary efficacy end point and additional reperfusion
results in lead-in patients did not statistically differ from
main-study phase patient results (Table VII in the Data
Supplement).

Primary Safety End Point
In the primary analysis main-study phase population, the
rate for the primary safety composite end point of combined sICH and 90-day all-cause mortality was 18.1%
(95% CI, 11.1%–25.1%, Table 3), compared with the
PG of 30.4% and historical rate of 20.4% (noninferiority P=0.004; superiority P=0.57). The primary safety
end point in lead-in patients did not statistically differ
from main-study phase patient results (Table VIII in the
Data Supplement).

General anesthesia

49 (41.9%)

73 (45.6%)

BGC use only

25 (21.4%)

43 (26.9%)

Secondary End Points

BGC+intermediate catheter use

10 (29.9%)

56 (35%)

Intermediate catheter use only

21 (17.9%)

28 (17.5%)

Secondary clinical efficacy outcomes are shown in
Table 2. In main-study phase patients, good clinical
outcome (functional independence, mRS score 0–2)
was attained by 58.0% (95% CI, 48.3%–67.3%), a rate
superior to the 43.5% in the pooled comparator trials
(P=0.006). The full distribution of disability levels at 90
days is shown in Figure 2B. Health-related quality of life
on the EQ-5D at 90 days was median 80 (IQR, 70–90)
and granular disability level on the Academic Medical

ASPECTS indicates Alberta Stroke Program Early CT Score; BGC, balloon
guide catheter; CAD, coronary artery disease; IQR, interquartile range; MI, myocardial infarction; mRS, modified Rankin Scale; TIGER, Treatment With Intent to
Generate Endovascular Reperfusion; and tPA, tissue-type plasminogen activator.

performance goal and the 73.4% historical rate (noninferiority P<0.0001; superiority P<0.01; Table 2, Figure IIB
in the Data Supplement).
1538   May 2021
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Table 2. Angiographic and Clinical Efficacy Outcomes in
Main-Study and Combined Lead-In/Main-Study Patients

Main-study
(n=117)

All (n=160)

99 (84.6%)

130 (81.3%)

(95% CI,
78.1%–91.2%)

(95% CI,
75.2%–87.3%)

Primary efficacy end point
 Successful reperfusion
(mTICI 2b-3 within 3
Tigertriever passes without
rescue), n (%)

Angiographic outcomes within 3 Tigertriever passes
 Excellent reperfusion (mTICI
2c-3 within 3 Tigertriever
passes without rescue), n (%)

74 (63.2%)

94 (58.8%)

0

9 (7.7%)

17 (10.6%)

1

2 (1.7%)

2 (1.3%)

2a

7 (6%)

11 (6.9%)

2b

25 (21.4%)

36 (22.5%)

2c

28 (23.9%)

30 (18.8%)

3

46 (39.3%)

64 (40%)

Other angiographic and procedural outcomes
 Final successful reperfusion
(mTICI 2b-3)

112 (95.7%)

150 (93.8%)

 Final excellent reperfusion
(mTICI 2-3c)

84 (71.8%)

106 (66.3%)

  0

3 (2.6%)

4 (2.5%)

  1

0

0

  2a

2 (1.7%)

6 (3.8%)

  2b

28 (23.9%)

44 (27.5%)

  2c

35 (29.9%)

38 (23.8%)

  3

49 (41.9%)

68 (42.5%)

 First-pass successful reperfusion (mTICI 2b-3)*

67/116 (57.8%)

89/158 (56.3%)

 First-pass excellent reperfusion (mTICI 2c-3)*

48/116 (41.4%)

66/158 (41.8%)

33 (28.2%)

51 (31.9%)

 Time from puncture to mTICI
2b-3, median (IQR)

Use of rescue therapy‡

24 (16–38)

25 (17–43)

N=103

N=139

 Time from puncture to closure, median (IQR)†

43 (28-72.5)

48 (30-84)

65/112 (58%)

86/154 (55.8%)

(95% CI,
48.33%–67.29%)

(95% CI,
47.63%–63.83%)

0.80 (0.70–0.90)

0.80 (0.68–0.90)

(N=81)

(N=112)

93.3% (57.8-100)

93.3% (60.4–100)

77.3% (30.2%)

78.1% (30.0%)

(N=83)

(N=114)

Clinical outcomes
 90-d good outcome (mRS
score 0–2), n (%) (95% CI)

EQ-5D at 90 d, median (IQR)

 ALDS at 90 d, median (IQR),
mean (SD)

ALDS indicates Academic Medical Center Linear Disability Score; IQR, interquartile range; mRS, modified Rankin Scale; and mTICI, modified Thrombolysis
in Cerebral Ischemia.
*Angio after first pass was not available from 1 lead-in and 1 main-study
patient.
†Closure time was not available from 1 main-study patient.
‡Stentriever, aspiration retriever, IA tPA, angioplasty or stenting.
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Tigertriever Performance in Vessels of Different
Size
Tigertriever performance in smaller (<2 mm) and larger
(≥2 mm) vessels is shown in Table 4. Median vessel diameters were 1.6 mm (IQR, 1.5–1.8) for smaller vessels and
2.5 mm (IQR, 2.2–3.0) for larger vessels. Rates of both
the primary efficacy end point (successful reperfusion)
and the primary safety end point components (sICH at
24 hours and all-cause mortality at 90 days) were comparable in both vessel size groups.

DISCUSSION
In this prospective, multicenter trial, the Tigertriever
yielded high rates of reperfusion among patients with
acute ischemic stroke swith large vessel occlusion,
with substantial reperfusion achieved in >8 of every
10 patients with the Tigertriever alone and >9 of every
10 patients after additional interventions. The rate of
successful reperfusion surpassed the predefined performance goal against the predicate Trevo and Solitaire devices derived from regulatory registration and
additional pivotal trials. The high successful reperfusion
rates with the Tigertriever device translated to favorable
functional outcomes, with nearly 6 of every 10 patients
achieving functional independence at day 90.
Patients enrolled in the TIGER study were similar to the
comparator studies in several key features, including age,
presenting deficit severity (NIHSS), extent of ischemic
injury on initial imaging (Alberta Stroke Program Early CTs),
vascular risk factors, rate of pretreatment with tPA, and frequency of target occlusion in internal carotid artery and M1
middle cerebral artery (Table IV in the Data Supplement).
The frequency of M2 middle cerebral artery occlusions
was mildly higher in the present study than several comparator studies but lower than in the most recent comparator investigation, ARISE II.20 The greater proportion of M2
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Center Linear Disability Score at 90 days was median
93.3 (IQR, 57.8–100).
Secondary safety outcomes are shown in Table 3.
Neurological deterioration by 4 or more NIHSS points
by 24 hours occurred in 7.7% (95% CI, 3.6%–14.2%).
The rate of embolization to a previously uninvolved new
territory was 2.6% (95% CI, 0.5%–7.4%), a rate superior
to the 7.4% in the pooled comparator trials (P=0.0403).
Asymptomatic intracranial hemorrhage within 24 hours
occurred in 31.0% (95% CI, 22.7%–40.3%). (Additional
data on radiological classification of hemorrhages are
shown in Tables IX and X in the Data Supplement.)
Secondary clinical efficacy and safety results in leadin patients did not statistically differ from main-study
phase patient results (Tables III and IV in the Data Supplement). All adverse events are shown in Table XI in the
Data Supplement.
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Figure 2. Reperfusion and functional outcomes in main-study phase of TIGER trial (Treatment With Intent to Generate
Endovascular Reperfusion).
A, Reperfusion degree after first pass, after up to 3 Tigertriever passes, and after rescue therapy. B, Distribution of 90-d global disability outcomes
on the modified Rankin Scale (mRS). mRS was available from 114 patients out of the 117 of the main-study group. mTICI indicates modified
Thrombolysis in Cerebral Ischemia.

occlusions reflects the increasing treatment of more distal
vessel occlusions in clinical practice.21 M2 occlusions have
features that make them both more difficult targets for
EVT, including distal location, smaller size, reduced accessibility, and less difficult, including smaller thrombus burden.
As the frequency of reperfusion of the M2 was similar to
other occlusion sites in the present study, the distribution
of target occlusions did not affect comparison with prior
studies. Patients in this study were treated sooner after
onset (last known well to puncture 2 hour 59 minutes)
than in prior studies, in accord with increasing emphasis in
national guidelines and national practice on accelerating
speed of endovascular thrombectomy.6–8
Reperfusion rates were better in the current study
than in the comparator studies in a variety of parameters, including first pass reperfusion, mean number of
passes, reperfusion after up to 3 passes before rescue
1540   May 2021

therapy, and final reperfusion after rescue therapy. First
pass effect, defined as achieving mTICI 2c-3 reperfusion
with one pass of the stent retriever, is likely to yield better patient outcomes and is a stringent metric to assess
device performance.22 In the current study, a first pass
effect was achieved in 41.4% of patients, which compares
favorably to the rate of 25% in both the North American
Solitaire Acute Stroke registry23 and Trevo acute ischemic stroke registry.24 In the ARISE II study, the first pass
effect was seen in 40% of patients,20 which is comparable to the present study. In the current study, successful
reperfusion at procedure end, including rescue therapies,
was achieved in nearly every patient (96%), a value that
elevates cerebral reperfusion success rates to those of
cardiac reperfusion procedures.25,26
Faster time from puncture to achievement of reperfusion has been associated with improved clinical
Stroke. 2021;52:1534–1544. DOI: 10.1161/STROKEAHA.121.034436
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Table 3.

Safety End Points in Main-Study and Combined Lead-In/Main-Study Patients

Main-study (n=117)

All (n=160)

21 (18.1%)

31/159* (19.5%)

(95% CI, 11.1%–25.1%)

(95% CI, 13.3%–25.7%)

2 (1.7%)

3 (1.9%)

(95% CI, 0.2%–6.03%)

(95% CI, 0.39%–5.38%)

21 (18.1%)

31/159* (19.5%)
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TIGER

Primary safety composite end point, n (%)
 Symptomatic intracranial hemorrhage within 24 h
and 90 d all-cause mortality*
Secondary safety end points, n (%)
Symptomatic intracranial hemorrhage within 24 h†

90-d all-cause mortality*

(95% CI, 11.1%–25.1%)

(95% CI, 13.3%–25.7%)

Asymptomatic intracranial hemorrhage within 24 h

36 (31.0%)

50‡ (31.4%)

(95% CI, 22.7%–40.29%)

(95% CI, 24.32%–39.27%)

Neurological deterioration within 24 h

9 (7.7%)

14 (8.8%)

(95% CI, 3.61%–14.21%)

(95% CI, 4.9%–14.33%)

3 (2.6%)

4‡ (2.5%)

(95% CI, 0.53%–7.37%)

(95% CI, 0.69%–6.31%)

Embolization to new territory

CT indicates computed tomography; sICH, symptomatic intracranial hemorrhage; and TIGER, Treatment With Intent to Generate
Endovascular Reperfusion.
*One patient withdrew consent at the day 4 visit so did not contribute full to 90-d mortality assessment.
†All sICH events occurred in cases treated with Tigertriever plus rescue therapy.
‡N=159. Reduced sample size due to missing 24 h CT or final angiogram.

outcomes.27 The current study results demonstrate the
median procedure time (from puncture to achievement
of mTICI ≥2b) was 25 (IQR, 17–43) minutes, which compares favorably to the ARISE II study, where the median
time was 35 (IQR, 24–58) minutes.20 This time was
similar to the contact aspiration first pass thrombectomy
time of median 25 minutes as reported in the COMPASS
study (Aspiration Thrombectomy Versus Stent Retriever
Thrombectomy as First-Line Approach for Large Vessel Occlusion) but shorter than the median 35 minutes
reported for that trial’s stent retriever group.28 In experienced, high-volume centers performing over 48 thrombectomies annually, the median puncture-to-reperfusion
time with the Trevo device was 67 (IQR, 42–105) minutes.29 The reduced procedure times with the Tigertriever
may reflect in part the technological advancement of the
operator being able to adjust the radial force expansion
to interact with the clot in a more productive manner.

The use of a BGC in the proximal vessel of the target
occlusion when prior stent retrievers are deployed has
been shown to improve the first pass reperfusion effect
and clinical outcomes.30 The proximal flow arrest may
prevent distal embolization or non- target distal embolization. The unique design of the Tigertriever allows for
more effective internalization of the thrombus into the
interstices of the device. As the device is collapsed by
the operator, it theoretically limits the chance of distal
embolization as the clot is completely entwined in the
retriever. The current study had a lower rate of BGC use
at 35% in the intention to treat population, in comparison
to the ARISE II trial in which this technique was used in
73.6% of patients.20 Despite the lower use of BGC in
this study, there were only 4 patients (2.5%) who had
an embolization to a new territory compared with 6.6%
in ARISE II and to 7.4% in the pooled data from of MR
CLEAN,1 ARISE II,20 REVASCAT,3 and TREVO 2.13

Table 4. Tigertriever Performance in Vessels of Different Size Among Combined Lead-In/Main-Study
Patients
Vessel diameter <2 mm
(N=27)

Vessel diameter ≥2 mm
(N=133)

P Value

Vessel diameter, mean (SD), mm

1.58 (0.29)

2.71 (0.67)

…

Vessel diameter, median (IQR; range), mm

1.6 (IQR, 1.5–1.8)

2.5 (IQR, 2.2–3)

…

(Range, 0.7–1.9)

(Range, 2.0–6.0)

Successful reperfusion (mTICI 2b-3) within 3 Tigertriever passes without rescue), n (%)

23 (85.2%)

107 (80.4%)

0.79

90-d all-cause mortality, n (%)

3 (11.1%)

28 (21.0%)

0.29

sICH at 24 h, n (%)

0 (0%)

3 (2.2%)

1.00

IQR indicates interquartile range; mTICI, modified Thrombolysis in Cerebral Ischemia; and sICH, symptomatic intracranial hemorrhage.
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Clinical outcomes in the present study were favorable.
Functional independence (mRS score 0–2) at 90 days
was achieved in 58% of patients, a rate higher than in
the comparator studies. Similarly, health-related quality of
life showed a utility value of 0.80, higher than the 0.57
in the MR CLEAN trial.31 These high rates of good longterm functional outcome likely reflect reduced total brain
ischemia time because of high achieved reperfusion
rates, early last known well-to-punctures times, and rapid
puncture-to-reperfusion times. The faster last known
well-to-puncture times versus historical comparator trials
likely reflects interval evolution in endovascular workflow
and systems of care, while the increased perfusion rates
and rapid puncture-to-reperfusion times likely at least in
part reflect intrinsic properties of the Tigertriever itself.

Limitations
This study has limitations. The study design was a singlearm trial against objective performance criteria derived
from pooled prior studies of predicate devices, rather than
a randomized trial with a contemporaneous control group.
This approach constrains precision in delineating how
well the Tigertriever compares with any particular comparator device. Reflecting the single-arm design, the central imaging and site clinical outcome evaluators and were
not blinded to treatment assignment. However, for imaging the use of a central core laboratory was employed to
mitigate any resulting bias. Similarly, for clinical outcomes,
the primary efficacy outcome was performed by certified
raters using a structured assessment system (the Rankin
Focused Assessment) and the congruence of rater
assessments of global disability and patient-reported
health-related quality of life indicates accurate scoring.

Conclusions
In this prospective, multicenter study with a unique operator-controlled stent retriever, the Tigertriever achieved
successful reperfusion within 3 passes in >8 of every
10 patients, demonstrating noninferiority over a performance goal and superiority over actual historical rates
derived from trials and prospective studies of established
devices. In addition, first pass successful reperfusion was
achieved in nearly 6 of every 10 patients and final successful reperfusion in >9 of every 10 patients. Rates of
embolization to a new territory and sICH were low and
rates of good global disability and health-related quality
of life outcomes high. Efficacy and safety outcomes were
similar in vessels with diameters <2 and ≥2 mm.
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